CANCER BIOMARKER ANALYSIS IN BLOOD

ONCOLOGY

To support drug discovery projects in oncology, we perform high-content analysis either in cellular models of human tumors in 2D or 3D, or directly in tumor tissues and blood samples. Combining a panel of validated assays for immediate performance and more than 10-year experience in assay development, we assist pharmaceutical companies and academic researchers in the discovery of new cancer drug targets, the identification of new anticancer compounds, and the quantitative analysis of novel cancer biomarkers.

CANCER BIOMARKER ANALYSIS IN BLOOD

Fluofarma quantifies cancer biomarkers in blood samples to support in vivo studies and clinical trials in oncology. Specialized in the multiplexed detection of cell surface and intracellular markers by flow cytometry, we can validate new blood biomarkers, perform pharmacokinetics studies, assess treatment response, or stratify patients in trials.

BLOOD AND PBMC SOURCING

 

Although we mainly conduct biomarker studies in blood samples provided by our clients, we can obtain and analyze blood samples from external sources:

 

> Fresh blood from healthy donors, through an agreement with the French Blood Bank.

> Blood samples from patients with specific tumors, through a partnership with a comprehensive cancer center.

FLOW CYTOMETRY SERVICES FOR BIOMARKER DETECTION IN BLOOD


> Accurate multiplexed immunophenotyping: identification of specific cell subpopulations through the detection of cell surface proteins

> Multiplexed intracellular biomarker detection: simultaneous assessment of multiple signaling pathways in individual cells, through the detection intracellular markers and phosphoproteins.

> Automated & high-throughput analysis using 3-laser flow cytometry and proprietary software applications for data analysis and visualization.